SG11201809551TA - Selection of bacterial strains useful in allergy treatment - Google Patents
Selection of bacterial strains useful in allergy treatmentInfo
- Publication number
- SG11201809551TA SG11201809551TA SG11201809551TA SG11201809551TA SG11201809551TA SG 11201809551T A SG11201809551T A SG 11201809551TA SG 11201809551T A SG11201809551T A SG 11201809551TA SG 11201809551T A SG11201809551T A SG 11201809551TA SG 11201809551T A SG11201809551T A SG 11201809551TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- bacterial strains
- allergy
- rule
- treatment
- Prior art date
Links
- 230000001580 bacterial effect Effects 0.000 title abstract 5
- 206010020751 Hypersensitivity Diseases 0.000 title abstract 4
- 208000026935 allergic disease Diseases 0.000 title abstract 4
- 230000007815 allergy Effects 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 title abstract 4
- 102000011107 Diacylglycerol Kinase Human genes 0.000 abstract 3
- 108010062677 Diacylglycerol Kinase Proteins 0.000 abstract 3
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 102100021580 Active regulator of SIRT1 Human genes 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 101150026963 RPS19BP1 gene Proteins 0.000 abstract 1
- 229940071604 biogaia Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650620 | 2016-05-09 | ||
| PCT/SE2017/050455 WO2017196235A1 (en) | 2016-05-09 | 2017-05-08 | Selection of bacterial strains useful in allergy treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809551TA true SG11201809551TA (en) | 2018-11-29 |
Family
ID=58873850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809551TA SG11201809551TA (en) | 2016-05-09 | 2017-05-08 | Selection of bacterial strains useful in allergy treatment |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11135255B2 (enExample) |
| EP (1) | EP3454874A1 (enExample) |
| JP (1) | JP7030716B2 (enExample) |
| CN (1) | CN109195612A (enExample) |
| AU (1) | AU2017262408A1 (enExample) |
| BR (1) | BR112018072511A2 (enExample) |
| CA (1) | CA3023867A1 (enExample) |
| CL (1) | CL2018003167A1 (enExample) |
| MX (1) | MX392754B (enExample) |
| SG (1) | SG11201809551TA (enExample) |
| WO (1) | WO2017196235A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022007925A (es) * | 2019-12-24 | 2022-09-29 | Univ Iowa State Res Found Inc | Control de histamina para promover la salud y controlar la enterocolitis usando composiciones probioticas y/o enzimas, que degrada histamina. |
| JP7515153B2 (ja) * | 2020-03-06 | 2024-07-12 | 学校法人麻布獣医学園 | 乳酸菌含有組成物 |
| CN113073066B (zh) | 2021-04-16 | 2022-01-04 | 段云峰 | 罗伊氏乳杆菌及其应用、组合物、药物和食品 |
| CN114317326B (zh) * | 2021-12-06 | 2023-09-12 | 浙江工商大学 | 一种用于缓解过敏反应的清酒乳杆菌及制备方法 |
| CN115025130A (zh) * | 2022-06-02 | 2022-09-09 | 广东南芯医疗科技有限公司 | 罗伊氏乳杆菌e9在制备治疗或预防过敏性疾病药物中的应用 |
| CN116376758B (zh) * | 2023-03-15 | 2024-07-02 | 广东南芯医疗科技有限公司 | 詹氏乳杆菌ls06及其在制备治疗或预防过敏性疾病药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO155805C (no) * | 1981-02-06 | 1987-06-10 | Ucb Sa | Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter. |
| JP4212838B2 (ja) * | 2002-06-26 | 2009-01-21 | カルピス株式会社 | 抗アレルギー剤 |
| AU2002951270A0 (en) * | 2002-09-06 | 2002-09-19 | Vri Biomedical Ltd | Probiotic Bacterium and Methods of Use |
| KR100507417B1 (ko) * | 2003-01-27 | 2005-08-10 | (주) 피엘바이오 | 알레르기 질환 예방 및 치료 기능을 가진 유산균과 이를 함유한 항알레르기 제품 |
| EP1812113A1 (en) * | 2004-11-11 | 2007-08-01 | Argenta Discovery Limited | Pyrimidine compounds as histamine modulators |
| EP2674493B1 (en) * | 2006-04-13 | 2017-12-27 | Arrowhead Research Corporation | RNAi-mediated inhibition of histamine receptor H1-related conditions |
| JP2008127365A (ja) * | 2006-11-24 | 2008-06-05 | Kowa Co | アレルギー性疾患の予防及び／又は治療剤 |
| WO2010020057A1 (en) * | 2008-08-18 | 2010-02-25 | Manel Jordana | Treatment and/or Prevention of Peanut Induced Anaphylaxis |
| JP2011254773A (ja) * | 2010-06-11 | 2011-12-22 | Bio Plan:Kk | 乳酸菌の菌株及びこれを利用したアレルギー抑制剤 |
| WO2012012390A1 (en) * | 2010-07-19 | 2012-01-26 | Marvphyt Development Llc | Botanical composition and methods of manufacture and use |
| US20130022586A1 (en) * | 2011-07-21 | 2013-01-24 | James Versalovic | Production and use of bacterial histamine |
| US20160000777A1 (en) * | 2013-02-21 | 2016-01-07 | University Of Rochester | Methods of using histamine receptor agonists and antagonists |
| JP6195268B2 (ja) * | 2013-07-18 | 2017-09-13 | 国立大学法人徳島大学 | 鼻炎の予防治療装置 |
| JP2018510631A (ja) * | 2015-03-26 | 2018-04-19 | バイオガイア・エイビーＢｉｏｇａｉａ ＡＢ | ヒスタミン産生細菌株及びがんにおけるそれらの使用 |
-
2017
- 2017-05-08 JP JP2018558668A patent/JP7030716B2/ja active Active
- 2017-05-08 AU AU2017262408A patent/AU2017262408A1/en not_active Abandoned
- 2017-05-08 BR BR112018072511A patent/BR112018072511A2/pt not_active Application Discontinuation
- 2017-05-08 MX MX2018013660A patent/MX392754B/es unknown
- 2017-05-08 CA CA3023867A patent/CA3023867A1/en active Pending
- 2017-05-08 EP EP17727008.9A patent/EP3454874A1/en not_active Ceased
- 2017-05-08 SG SG11201809551TA patent/SG11201809551TA/en unknown
- 2017-05-08 US US16/099,258 patent/US11135255B2/en active Active
- 2017-05-08 CN CN201780028567.1A patent/CN109195612A/zh active Pending
- 2017-05-08 WO PCT/SE2017/050455 patent/WO2017196235A1/en not_active Ceased
-
2018
- 2018-11-08 CL CL2018003167A patent/CL2018003167A1/es unknown
-
2021
- 2021-08-31 US US17/462,227 patent/US12201656B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3454874A1 (en) | 2019-03-20 |
| JP7030716B2 (ja) | 2022-03-07 |
| WO2017196235A1 (en) | 2017-11-16 |
| CN109195612A (zh) | 2019-01-11 |
| US20190142877A1 (en) | 2019-05-16 |
| US11135255B2 (en) | 2021-10-05 |
| BR112018072511A2 (pt) | 2019-03-12 |
| MX392754B (es) | 2025-03-24 |
| AU2017262408A1 (en) | 2018-11-15 |
| CL2018003167A1 (es) | 2018-12-21 |
| US20220008491A1 (en) | 2022-01-13 |
| MX2018013660A (es) | 2019-02-28 |
| US12201656B2 (en) | 2025-01-21 |
| JP2019520801A (ja) | 2019-07-25 |
| CA3023867A1 (en) | 2017-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201805835WA (en) | Modified oncolytic virus | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201811579VA (en) | Chemiluminescent substrates | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201808476SA (en) | Recycling of polymer matrix composite | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201906630SA (en) | Wellhead assembly and method | |
| SG11201903833VA (en) | Tray system for transfer, counting, storage and disposal of surgical instruments | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201903786UA (en) | Farnesyltransferase inhibitors for use in methods of treating cancer | |
| SG11201908091QA (en) | Aqueous anti-pd-l1 antibody formulation | |
| SG11201907950VA (en) | Complexes for treating sensitivity | |
| SG11201900515PA (en) | Succinate forms and compositions of bruton's tyrosine kinase inhibitors | |
| SG11201806161TA (en) | Antibodies for il-17c | |
| SG11201811763SA (en) | B-cell-mimetic cells |